-
Mycobacterium Tuberculosis(Sputum/Tongue swab sample)
Tuberculosis (TB), caused by Mycobacterium tuberculosis, primarily affects the lungs, with around 10 million new cases annually as of July 2024. Traditional testing methods are often impractical for rapid diagnosis. Our Mycobacterium Tuberculosis Nucleic Acid Test Card offers a user-friendly solution for detecting MTBC DNA in sputum or tongue swab samples, enabling timely diagnosis and management.¥ 0.00More >
-
SARS-CoV-2/FIu A/Flu B
With the rise of respiratory illnesses like COVID-19, Flu A, and Flu B, efficient and accurate testing is vital. As of July 2024, SARS-CoV-2 has caused over 760 million cases worldwide, and seasonal flu affects millions each year. Quick, precise diagnosis is key to effective management. Traditional methods can be cumbersome for rapid, frequent testing.
This kit provides a streamlined solution for in vitro detection of SARS-CoV-2, Influenza A, and Influenza B RNA in nasal swab samples.¥ 0.00More >
-
HPV 16/18/45
HPV types 16, 18, and 45 are linked to various cancers, notably cervical cancer, with types 16 and 18 causing about 70% of cases. With over 600,000 new cervical cancer cases annually as of July 2024, early screening is crucial. Traditional methods are slow, delaying follow-up and treatment.
This kit offers rapid detection of HPV types 16, 18, and 45 DNA in cervical and vulvovaginal swabs, aiding early diagnosis and cancer prevention.¥ 0.00More >
-
SARS-CoV-2
Traditional large testing equipment is often impractical for frequent, quick tests. Quick and accurate testing methods are essential for timely diagnosis and effective management of COVID-19 cases. Accurate COVID-19 diagnosis is crucial due to its global impact and high transmission rates.
This kit provides in vitro qualitative detection of the N gene and ORF1ab gene of SARS-CoV-2 in nasal swabs from suspected COVID-19 cases.¥ 0.00More >
-
把疾病检测实验室，装进小盒子| 果壳 科技有意思
把疾病检测实验室，装进小盒子2024-10-12
more
-
Pluslife Biotech Founder, Prof. Songyang Speaks on Next-Generation Molecular POCT Technology at the International Health Industry Forum of Boao Forum for Asia
From April 20th to 21st, the International Health Industry Forum of Boao Forum for Asia was held in Beijing, China. The event brought together decision-makers, healthcare providers, experts, and investors to promote global innovation and development in healthcare. The Founder of Pluslife Biotech, Prof. SONGYANG Zhou spoke on the panel “Diagnostic Companies and How They Engage with Global Public Health” to share ideas on how Next-Generation Molecular POCT2024-08-05
more
-
Pluslife MiniDock Achieves Outstanding Accuracy and Usability in PATH APOLLO Project
In the recent APOLLO evaluation project conducted at the PATH laboratory in Seattle, Pluslife MiniDock has gained satisfactory results in terms of test performance and usability, confirming its testing accuracy and strong usability in LMICs (Low- and Middle-Income Countries).2024-08-05
more
-
Pluslife Biotech CEO, Mr. Chen, Shared Insights into Molecular POCT Empowering Global Primary Healthcare at Pujiang Innovation Forum
From September 9th to 11th, 2023, the 16th Pujiang Innovation Forum took place in Shanghai, China. Mr. CHEN Chong, the CEO of Pluslife Biotech, spoke on the panel titled “New Applications and Markets for Innovative Technologies Accelerating Global Health and Development” and shared insights into how molecular Point-of-Care diagnostics empower global primary healthcare.2024-08-05
more
-
Pluslife Biotech Founder, Prof. Songyang Contributes Viewpoints on Infectious Disease Prevention at the Symposium on Global Health
The 4th Symposium on Global Health was recently held in Beijing on September 14-15, 2023. The founder and head scientist of Pluslife Biotech, Prof. SONGYANG Zhou, gave a speech on the topic “New technologies for the surveillance and detection of infectious diseases” to deliver an outlook on strengthening global infectious disease diagnosis and surveillance with revolutionary molecular POCT technology.2024-08-05
more
